ImpediMed

ImpediMed Share Buybacks

The Share Buybacks of ImpediMed (IPD.AX) as of Oct 23, 2026 is -1.77 M AUD.

Share Buybacks

-1.77 MAUD

Last updated:

Share Buybacks of ImpediMed is 2026 -1.77 M AUD. Share Buybacks of ImpediMed was 2025 0.00 AUD. It decreases by % lower compared to the previous year.

The ImpediMed Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2019
-18,000.00 AUD
Jan 1, 2020
-2.68 M AUD
Jan 1, 2021
-133,000.00 AUD
Jan 1, 2022
-2.21 M AUD
Jan 1, 2023
-1.52 M AUD
Jan 1, 2024
-62,000.00 AUD
Jan 1, 2025
0.00 AUD
Jan 1, 2026
-1.77 M AUD
The ImpediMed Share Buybacks history
YEARShare BuybacksYoY
-1.77 MAUD—
0.00AUD-100.00%
-62,000.00AUD-95.91%
-1.52 MAUD-31.50%
-2.21 MAUD+1,563.91%
-133,000.00AUD-95.04%
-2.68 MAUD+14,783.33%
-18,000.00AUD-25.00%
-24,000.00AUD-22.58%
-31,000.00AUD-99.22%
-3.98 MAUD+97.81%
-2.01 MAUD+235.56%
-599,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Share Buybacks of ImpediMed is -1.77 M AUD in 2026.

On Eulerpool you can find the complete historical development of Share Buybacks ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ImpediMed

All Key Metrics — ImpediMed